1 / 25

Systemic Lupus Erythematosus

Systemic Lupus Erythematosus. BY ABDULLAH RADWAN. SLE. Autoimmune disease that affects multisystems 1.5 million cases of lupus Prevalence of 17 to 48 per 100,000 population Women > Men - 9:1 ratio 90% cases are women African Americans > Whites

cdobson
Télécharger la présentation

Systemic Lupus Erythematosus

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Systemic Lupus Erythematosus BY ABDULLAH RADWAN

  2. SLE • Autoimmune disease that affects multisystems • 1.5 million cases of lupus • Prevalence of 17 to 48 per 100,000 population • Women > Men - 9:1 ratio • 90% cases are women • African Americans > Whites • Onset usually between ages of 15 and 45 years, but • Can occur in childhood or later in life

  3. Clinical Manifestations • For the purpose of identifying patients in clinical studies, a person has SLE if 4 or more of the 11 criteria are present, serially or simultaneously, during any interval of observation. (specificity 95%, sensitivity 75%) • It is important to remember that a patient may have SLE and not have 4 criteria.

  4. Butterfly rash Discoid lupus Photosensitivity Oral ulcers Arthritis Serositis 7. Neurologic d/o 8. Hematologic d/o 9. Renal d/o 10.Immunologic: anti-DNA, anti-Sm, false pos STS 11.Anti-nuclear antibody Criteria

  5. Cutaneous • Most common rash is photosensitive, raised erythematous malar rash. 55-85% develop at some point in disease • Discoid Lupus Erythematosus (DLE): 15-30% circular, scaly hyperpimented lesions with erythematous rim, atrophic center—can be disfiguring • Mouth/vaginal/nasal ulcers • Alopecia: may be diffuse or patchy. Occurs 50%

  6. Malar Rash

  7. Discoid Rash

  8. Oral Ulcers

  9. MSK • Polyarthritis, mild to disabling, occurs most frequently in hands, wrists, knees. Occurs 90% • Joint deformities occur in only 10% • Arthritis of SLE tends to be transitory • If single joint has persistent pain, consider osteonecrosis (prevalence increased in SLE over general population, especially if on steroids.) • Myositis with elevated CK and weakness rarely occurs

  10. Arthritis

  11. Serositis - Pulmonary • Pleuritis with or without effusion - if case is mild, tx: NSAIDS - if case is severe, tx: steroids • Life-threatening manifestations: interstitial inflammation which can lead to fibrosis and intra-alveolar hemorrhage. • Also pneumothorax and pulmonary HTN can occur

  12. Serositis – Cardiac • Pericarditis: most common cardiac manifestation and usually responds to NSAIDs. • Myocarditis (rare) and fibrinous endocarditis (Libman-Sacks) may occur. Steroids plus treatment for CHF/arrhythmia or embolic events. • MI due to atherosclerosis can occur in <35 y/o

  13. Neuro • Cranial or peripheral neuropathy occurs in 10-15%, it is probably secondary to vasculitis in small arteries supplying nerves. • Diffuse CNS dysfunction: memory and reasoning difficulty • Headache: if excruciating, often indicate acute flare • Seizures of any type • Psychosis: must distinguish from steroid-induced psychosis (occurs in 1st weeks of tx at doses ≥40mg prednisone and resolves after several days of reducing or stopping tx)

  14. Cont. • TIA, Stroke: mostly increased among patients that are APLA positive • 50-fold increase in risk of vascular events in women under 45 compared to healthy women • Treatment for clotting event is long-term anticoagulation

  15. Heme • Anemia: usually Normochromic, normocytic • Leukopenia: almost always consists of lymphopenia, not granulocytopenia • Thrombocytopenia

  16. Renal • Nephritis: usually asymptomatic, so always check UA if patient has known or suspected SLE • Occurs early in course of disease-if not present w/in 1 yr, probably will not occur. • Histologic classification by renal biopsy is useful to plan therapy

  17. Histologic Classifications • Class I is minimal mesangial glomerulonephritis which is histologically normal on light microscopy but with mesangial deposits on electron microscopy. • Class II is based on a finding of mesangial proliferative lupus nephritis. This form typically responds completely to treatment with corticosteroids. • Class III is focal proliferative nephritis and often successfully responds to treatment with high doses of corticosteroids. • Class IV is diffuse proliferative nephritis. This form is mainly treated with corticosteroids and immunosuppressant drugs. • Class V is membranous nephritis and is characterized by extreme edema and protein loss. • Class VI Glomerulosclerosis

  18. Immunoglobulins • Anti-dsDNA IgG: very specific, may correlate with disease activity • Anti-Sm: specific, but only present in 25% of cases, does not correlate with activity • APLA: not specific. Used to identify patients at increased risk for clots, thrombocytopenia and fetal loss

  19. ANA • ANA: positive in 95% of cases. Pretest probability affects interpretation. In PCP setting, 2% for SLE. In rheum: 30% • Low Positive (1:160 or lower): SLE likelihood <2% (<26% for rheumatologists) • High Positive (1:320 or higher): SLE likelihood: 2-17% (32-81% for rheumatologists) • SLE specific patterns: Rim and Homogenous

  20. Additional work-up • Serum cr. and albumin • CBC w/ diff • U/A • ESR • Complement levels • Renal bx if warranted

  21. Treatment • Treatment plans are based on patient age, sex, health, symptoms, and lifestyle • Goals of treatment are to: -prevent flares -treat flares when they occur -minimize organ damage and complications

  22. Conservative management • For those w/out major organ involvement. • NSAIDs: to control pain, swelling, and fever • Caution w/ NSAIDS though. SLE pts are at increased risk for aseptic meningitis • Antimalarials: Generally to treat fatigue joint pain, skin rashes, and inflammation of the lungs • Commonly used: Hydroxycholorquine • Used alone or in combination with other drugs

  23. Cont. • Corticosteroids (Mainstay of SLE treatment) • To rapidly suppress inflammation • Usually start with high-dose IV pulse and convert to PO steroids with goal of tapering and converting to something else. • Commonly used: prednisone, hydrocortisone, methylprednisolone, and dexamethasone

  24. Immunosuppressives • Primarily for CNS/renal involvement • Mycophenolate mofetil (cellcept) • Azathioprine (imuran): requires several months to be effective, effective in smaller percentage of patients • MTX: for treatment of dermatitis and arthritis, not life-threatening disease • Cyclosporine: used in steroid-resistant SLE, risk of nephrotoxicity • Cyclophosphamide (cytoxan) Almost all trials performed on patients with nephritis

  25. THANK YOU

More Related